A completed study in patients with classic Hodgkin lymphoma (cHL) showed that DNMTi plus anti-PD-1 therapy is associated with high response rates and long-term benefits in patients with relapsed/refractory cHL who didn’t respond to PD-1 antibody therapy (165). This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.